| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa Mpred® |
Sun Pharma ANZ Pty Ltd |
Metastatic hormone sensitive prostate cancer |
Jul 2023 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Jul 2023 |
|
| ADALIMUMAB |
Ardalicip® |
Cipla Australia Pty Ltd |
Severe Crohn disease; moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa |
Jul 2023 |
|
| ATOGEPANT |
Aquipta® |
Allergan Australia Pty Ltd |
Prophylaxis of migraine |
Jul 2023 |
|
| AVACOPAN |
Tavneos® |
Vifor Pharma Pty Limited |
Severe active granulomatosis with polyangiitis (GPA) and severe active microscopic
polyangiitis (MPA) |
Jul 2023 |
|
| BUDESONIDE |
Jorveza® |
Dr Falk Pharma Australia Pty Ltd |
Eosinophilic oesophagitis (EoE) |
Jul 2023 |
|
| CABOTEGRAVIR |
Apretude® |
ViiV Healthcare Pty Ltd |
Pre-exposure prophylaxis of HIV infection |
Jul 2023 |
|
| CALCIPOTRIOL WITH BETAMETHASONE |
Enstilar® |
Leo Pharma Pty Ltd |
Chronic stable plaque type psoriasis vulgaris |
Jul 2023 |
|
| DAPAGLIFLOZIN |
Forxiga® |
AstraZeneca Pty Ltd |
Chronic heart failure |
Jul 2023 |
|
| DAUNORUBICIN WITH CYTARABINE |
Vyxeos® |
JAZZ PHARMACEUTICALS ANZ PTY LTD |
Acute myeloid leukaemia |
Jul 2023 |
|
| DUPILUMAB |
Dupixent® |
sanofi-aventis Australia Pty Ltd |
Chronic severe atopic dermatitis |
Jul 2023 |
|
| DURVALUMAB |
Imfinzi® |
AstraZeneca Pty Ltd |
Biliary tract cancer |
Jul 2023 |
|
| ENOXAPARIN |
|
Juno Pharmaceuticals Pty Ltd |
Thrombo-embolic disorders |
Jul 2023 |
|
| ESKETAMINE |
Spravato® |
Janssen-Cilag Pty Ltd |
Treatment resistant depression |
Jul 2023 |
|
| IXEKIZUMAB |
Taltz® |
Eli Lilly Australia Pty Ltd |
Non-radiographic axial spondyloarthritis (nr-AxSpA) |
Jul 2023 |
|
| LUMACAFTOR WITH IVACAFTOR |
Orkambi® |
Vertex Pharmaceuticals (Australia) Pty. Ltd. |
Cystic fibrosis |
Jul 2023 |
|
| MAVACAMTEN |
Camzyos® |
Bristol-Myers Squibb Australia Pty Ltd |
Hypertrophic cardiomyopathy |
Jul 2023 |
|
| MIRIKIZUMAB |
Omvoh® |
Eli Lilly Australia Pty Ltd |
Moderate to severe ulcerative colitis (MUSC) |
Jul 2023 |
|
| MOBOCERTINIB |
Exkivity® |
Takeda Pharmaceuticals Australia Pty. Ltd. |
Locally advanced or metastatic non-small cell lung cancer (NSCLC) |
Jul 2023 |
|
| MOLNUPIRAVIR |
Lagevrio® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Mild to moderate COVID-19 |
Jul 2023 |
|
| NIRAPARIB |
Zejula® |
GlaxoSmithKline Australia Pty Ltd |
Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Jul 2023 |
|
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Jul 2023 |
|
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Advanced or metastatic oesophageal squamous cell carcinoma |
Jul 2023 |
|
| NUSINERSEN |
Spinraza® |
Biogen Australia Pty Ltd |
Pre-symptomatic spinal muscular atrophy (SMA) |
Jul 2023 |
|
| OLAPARIB |
Lynparza® |
AstraZeneca Pty Ltd |
Ovarian cancer |
Jul 2023 |
|
| OLIPUDASE ALFA |
Xenpozyme® |
sanofi-aventis Australia Pty Ltd |
Acid sphingomyelinase deficiency (ASMD) |
Jul 2023 |
|
| ONASEMNOGENE ABEPARVOVEC |
Zolgensma® |
Novartis Pharmaceuticals Australia Pty Limited |
Presymptomatic treatment of spinal muscular atrophy (SMA) |
Jul 2023 |
|
| PATISIRAN |
Onpattro® |
Alnylam Australia Pty Ltd |
Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) |
Jul 2023 |
|
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Breast cancer |
Jul 2023 |
|
| POMALIDOMIDE |
PomolideTM |
Juno Pharmaceuticals Pty Ltd |
Relapsed/refractory multiple myeloma |
Jul 2023 |
|
| RAVULIZUMAB |
Ultomiris® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Atypical haemolytic uraemic syndrome (aHUS) |
Jul 2023 |
|
| RAVULIZUMAB |
Ultomiris® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Paroxysmal nocturnal haemoglobinuria (PNH) |
Jul 2023 |
|
| RELATLIMAB AND NIVOLUMAB |
Opdualag® |
Bristol-Myers Squibb Australia Pty Ltd |
Melanoma |
Jul 2023 |
|
| SACITUZUMAB GOVITECAN |
Trodelvy® |
Gilead Sciences Pty Limited |
Hormone receptor positive (HR+) human epidermal growth factor receptor-2 negative
(HER2-) advanced or metastatic breast cancer |
Jul 2023 |
|
| SECUKINUMAB |
Cosentyx® |
Novartis Pharmaceuticals Australia Pty Limited |
Hidradenitis Suppurativa (HS) |
Jul 2023 |
|
| SELPERCATINIB |
Retevmo® |
Eli Lilly Australia Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Jul 2023 |
|
| SOMAPACITAN |
Sogroya® |
Novo Nordisk Pharmaceuticals Pty. Limited |
Paediatric growth hormone deficiency (GHD) |
Jul 2023 |
|
| SONIDEGIB |
Odomzo® |
Sun Pharma ANZ Pty Ltd |
Metastatic or locally advanced basal cell carcinoma (BCC) |
Jul 2023 |
|
| TAFAMIDIS |
Vyndamax® |
Pfizer Australia Pty Ltd |
Transthyretin amyloid cardiomyopathy |
Jul 2023 |
|
| TAGRAXOFUSP |
Elzonris® |
A.Menarini Australia Pty Limited |
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
Jul 2023 |
|
| TIRZEPATIDE |
Mounjaro® |
Eli Lilly Australia Pty Ltd |
Type 2 Diabetes Mellitus (T2D) |
Jul 2023 |
|
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
AstraZeneca Pty Ltd |
Human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer
(mBC) |
Jul 2023 |
|
| TRIENTINE |
Trientine Dr.Reddy's® |
Dr Reddy's Laboratories (Australia) Pty Ltd |
Wilson disease |
Jul 2023 |
|
| UPADACITINIB |
Rinvoq® |
AbbVie Pty Ltd |
Crohn disease (CD) |
Jul 2023 |
|
| USTEKINUMAB |
Stelara® |
Janssen-Cilag Pty Ltd |
Fistulising Crohn disease |
Jul 2023 |
|
| VARICELLA ZOSTER VIRUS RECOMBINANT VACCINE |
Shingrix® |
GlaxoSmithKline Australia Pty Ltd |
Prevention of herpes zoster and post-herpetic neuralgia |
Jul 2023 |
|
| ZOLEDRONIC ACID |
APO-Zoledronic Acid® |
Apotex Pty Ltd |
Breast cancer |
Jul 2023 |
|